Consideration of an individual for membership in the University of Arizona Cancer Center (UACC) requires a major interest in promoting the mission of the UACC.
There are two membership categories – Member and Associate.
Full-time faculty who serve as PI or Project Leader of cancer-relevant peer-reviewed research grants; team science investigator (i.e., radiology, pathology) who is typically listed as co-investigator (e.g., >20% on multiple cancer grants), or
A leader in cancer research as evidenced by serving as:
- PI of interventional cancer trial that is investigator-initiated and institutionally funded, Or
- PI of an industry-sponsored trial for which the member was a primary scientific contributor to the trial’s design, implementation, and monitoring, Or
- Site PI of a multi-site trial initiated by an investigator at another center and accrues 5/10 or more accruals per year, Or
- Holds national leadership position in NCI National Clinical Trials Network studies (National PI or Study Chair, PI on U10 grant, NCTN (or nationally recognized consortium) Committee Chair, Or
New recruit or investigator in cancer research (3- to 4-year initial term) or researcher active in another field and has gained interest in pursuing cancer-relevant research
- Faculty who do not meet the criteria to be included in the CCSG application but are actively involved in UACC’s overall research efforts. Associate Members must meet the following criteria: Not involved in cancer research but is actively engaged in patient care or plays a leadership role (e.g., Shared Resource Director, physician leader) that is critical to the success of the cancer center.
* Under exceptional circumstances Members with appointments in other fiscally responsible institutions may be granted membership status as allowed by the sponsor and approved by the Program Leader and the Center Director according to the sponsor guidelines:
“Collaborators from other NCI-designated Cancer Centers or research institutions may become Center and program members. While the funded research projects of these members cannot count toward the funding base of the Program or the Center, these members may have full access to shared resources and developmental funds.”
General Membership Privileges Include:
- Eligibility for research space in Cancer Center buildings under the authority of the Director and the UACC Space Committee
- Membership listing on UACC website
- Access to Shared Resources and Common Equipment and priority use/rate for the following UACC SharedResources and Developing Research Cores and Services:
- Analytical Chemistry
- Behavioral Measurements and Intervention
- Cancer Imaging
- Experimental Mouse
- Flow Cytometry
- Gene Editing Facility
- Human Immune Monitoring Facility
- Tissue Acquisition and Cellular/MolecularAnalysis
- Clinical Protocol and Data Management services to including cancer clinical trial support of data management, pre- and post-award support, and protocol development assistance
- Access to pre-award administrative services for multi-investigator, center-wide PPG proposals (P01 and P50s)
- Waiver of registration fees for all UACC-sponsored conferences and retreats
- Notification of available research awards, conferences, and seminars
- Scientific and technical review of proposed research by scientific Program Members
- Increased visibility through the UACC Public Affairs Office
- Application for developmental funds, pilot project funding, and other special award funding through the UACC
- Acknowledge the CCSG, P30CA023074, in manuscripts and presentations that
- contain results obtained in the CCSG shared resources, or
- receive CCSG supplement funds, or
- pilot projects that are funded by CCSG Developmental funds such as Basic-Clinical Research Partnerships
- All members must actively participate in one of the UACC scientific Programs. This includes but is not limited to authorship of collaborative cancer-related manuscripts, development of new research projects, intra– and inter– programmatic project collaboration, attendance at the UACC Program meetings, sponsored conferences, and seminars.
|Research Program||Program Leaders|
|Therapeutic Development||William Montfort, PhD; Julie Bauman, MD, MPH|
|Cancer Imaging||Jennifer Barton, PhD; Dongkyun Kang, PhD|
|Cancer Biology||Cynthia Miranti, PhD; Nathan Ellis, PhD|
|Cancer Prevention & Control||Sherry Chow, PhD; Cynthia Thomson, PhD, RD|
- Clinicians must actively participate in established UACC multidisciplinary clinics, tumor boards, disease- oriented teams (DOTs), clinical trial meetings, and other UACC-sponsored clinical and educational programmatic activities.
- All members must submit all cancer-related studies involving humans and/or human specimens/data to theUACC’s Protocol Review and Monitoring Committee (PRMC) prior to submission to the Institutional Review Board. All members’ cancer clinical trials will be routinely reviewed for accrual by the PRMC. The policies and procedures for the PRMC are available on the UACC website.
- All members conducting clinical trials must provide information on cancer clinical studies (patient data, adverse events, protocol deviations, copies of IRB approval letters, revised protocols, audit reports, etc.) regardless of whether or not they utilize the UACC Clinical Trials Office.
- All members conducting clinical trials must provide copies of IRB submissions in regards to serious adverse events, protocol deviations, and audit reports regardless if they utilize the UACC Clinical Trials Office or not.
- Provide information annually to the UACC, or as required, to fulfill the CCSG applications to the National Cancer Institute including:
- Updated Biosketches (with funding support)
- Updated research interests
- Copies of all published research papers and abstracts
- Information on clinical studies
- Shared Resource service usage
- Progress reports (as applicable)
- Prompt response to surveys from the Office of Administration
- All members must communicate to Program Leaders and Administration any major new cancer-related discoveries and honors
- Participation with communication and development-related activities
Individual applications are evaluated by Administration, recommended or rejected by the Program Leader, and finally approved by the University of Arizona Cancer Center Director. Applicants receive notification of the decision on their applications up to ten weeks after application submission.
Review of New Applications and Renewal of Membership
Membership is reviewed annually by the University of Arizona Cancer Center Membership Committee and membership categories may be reassigned based on current review of category criteria and updated member information. Membership reassignment recommendations will then be sent to the University of Arizona Cancer Center Director for approval. The Director has final authority for approval, disapproval, or termination of membership.